Search clinical trials for: Miglustat (AT2221)
Total 98 results
-
Amicus TherapeuticsAvailable
-
Amicus TherapeuticsActive, not recruitingPompe Disease (Late-onset)United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
-
Amicus TherapeuticsActive, not recruitingPompe DiseaseUnited States, Netherlands, United Kingdom, Australia, Germany, New Zealand
-
Amicus TherapeuticsRecruitingPompe Disease (Late-onset)United States, Taiwan, Japan, Australia, Canada
-
Amicus TherapeuticsRecruitingGlycogen Storage Disease Type II Infantile OnsetTaiwan, United States, France, Germany, Italy, United Kingdom
-
Amicus TherapeuticsApproved for marketingPhysician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry DiseaseFabry DiseaseUnited States, Australia
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
UNION therapeuticsCompletedAtopic DermatitisBulgaria, Denmark, Poland
-
Amicus TherapeuticsAvailablePompe Disease Infantile-OnsetTaiwan, United States, Italy
-
Amicus TherapeuticsRecruitingFabry DiseaseSpain, United States, Japan, Australia, France, Portugal
-
Amicus TherapeuticsRecruiting
-
UNION therapeuticsCompleted
-
UNION therapeuticsCompleted
-
Amicus TherapeuticsActive, not recruitingFabry DiseaseUnited States, United Kingdom
-
Amicus TherapeuticsCompletedFabry DiseaseAustralia, Brazil
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States
-
Amicus TherapeuticsTerminatedFabry DiseaseUnited Kingdom, United States, Australia, Brazil, France
-
Amicus TherapeuticsCompletedFabry DiseaseFrance, United Kingdom
-
UNION therapeuticsCompletedIrritation Potential of Topic AgentUnited States
-
UNION therapeuticsCompletedAtopic DermatitisCanada
-
Amicus TherapeuticsRecruitingPompe DiseaseUnited States
-
Assistance Publique - Hôpitaux de ParisActelion; CRCM (Centres de Ressources et de Compétences de la Mucoviscidose)Completed
-
Manchester University NHS Foundation TrustNorthern Care Alliance NHS Foundation TrustActive, not recruiting
-
Amicus TherapeuticsTerminatedType 1 Gaucher DiseaseUnited States, United Kingdom
-
Genzyme, a Sanofi CompanyCompleted
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States, Australia, France, United Kingdom, Brazil, Canada
-
Amicus TherapeuticsTerminatedFabry DiseaseAustralia, United States, Italy, Spain, Belgium, Turkey, Brazil, Argentina, United Kingdom, Denmark, France, Canada, Egypt
-
Genzyme, a Sanofi CompanyCompletedGaucher DiseaseUnited States
-
Amicus TherapeuticsCompletedFabry DiseaseUnited States, Italy, Spain, Turkey, Brazil, Canada, United Kingdom, France, Poland, Australia, Egypt, Argentina, Denmark
-
SanofiCompletedGaucher DiseaseUnited States
-
Genzyme, a Sanofi CompanyCompletedGaucher DiseaseCanada, Russian Federation, Tunisia
-
Genzyme, a Sanofi CompanyCompletedGaucher DiseaseUnited States, Sweden, India, Netherlands, Austria, Japan, China, Serbia, France, Croatia, Australia, Portugal, Canada, Brazil, Greece, Romania, Russian Federation
-
Amicus TherapeuticsCompletedFabry DiseaseUnited Kingdom, United States
-
Devintec SaglMeditrial SrLRecruiting
-
Amicus TherapeuticsCompletedFabry DiseaseCanada, Belgium, United States, Australia, Netherlands
-
Genzyme, a Sanofi CompanyCompleted
-
ActelionCompleted
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1 | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease | Gaucher Disease, Non-Neuronopathic FormUnited States, Israel, Mexico, Russian Federation, Argentina, Italy
-
SanofiActive, not recruitingGaucher's Disease Type III | Gaucher's Disease Type ICanada, Argentina, France, Italy, Japan, Russian Federation, Spain, Sweden, Turkey, United Kingdom
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedContraceptionUnited States
-
Agios Pharmaceuticals, Inc.Celgene CorporationCompleted
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1United States, United Kingdom, Bulgaria, Canada, Colombia, India, Israel, Lebanon, Mexico, Russian Federation, Serbia, Tunisia
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1United States, France, Germany, Italy, Brazil, Australia, Argentina, Canada, Egypt, Russian Federation, Spain, United Kingdom
-
Amicus TherapeuticsCompletedFabry DiseaseFrance, Austria, United States, Belgium, Japan, United Kingdom, Denmark, Brazil, Australia, Italy
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsTerminatedTay-Sachs Disease | Sandhoff Disease | GM1 Gangliosidoses | GM2 GangliosidosesUnited States
-
Amicus TherapeuticsCompleted
-
The Hospital for Sick ChildrenActelionCompletedGangliosidoses GM2Canada
-
Children's National Research InstituteActelionCompletedSandhoff Disease | GM2 Gangliosidoses | Tay-SachsUnited States